Atea Pharmaceuticals (AVIR) Competitors $2.90 -0.01 (-0.17%) As of 12:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVIR vs. COLL, NTLA, RCUS, AVDL, SYRE, PHVS, CVAC, CRMD, NAGE, and BCAXShould you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), Arcus Biosciences (RCUS), Avadel Pharmaceuticals (AVDL), Spyre Therapeutics (SYRE), Pharvaris (PHVS), CureVac (CVAC), CorMedix (CRMD), Niagen Bioscience (NAGE), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry. Atea Pharmaceuticals vs. Collegium Pharmaceutical Intellia Therapeutics Arcus Biosciences Avadel Pharmaceuticals Spyre Therapeutics Pharvaris CureVac CorMedix Niagen Bioscience Bicara Therapeutics Atea Pharmaceuticals (NASDAQ:AVIR) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations, community ranking and risk. Is AVIR or COLL more profitable? Collegium Pharmaceutical has a net margin of 14.78% compared to Atea Pharmaceuticals' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 104.67% beat Atea Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Atea PharmaceuticalsN/A -34.90% -32.38% Collegium Pharmaceutical 14.78%104.67%18.38% Do institutionals & insiders hold more shares of AVIR or COLL? 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 18.1% of Atea Pharmaceuticals shares are held by company insiders. Comparatively, 2.5% of Collegium Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor AVIR or COLL? Collegium Pharmaceutical received 372 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 65.38% of users gave Collegium Pharmaceutical an outperform vote while only 47.50% of users gave Atea Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAtea PharmaceuticalsOutperform Votes1947.50% Underperform Votes2152.50% Collegium PharmaceuticalOutperform Votes39165.38% Underperform Votes20734.62% Do analysts rate AVIR or COLL? Atea Pharmaceuticals presently has a consensus price target of $6.00, suggesting a potential upside of 107.25%. Collegium Pharmaceutical has a consensus price target of $43.80, suggesting a potential upside of 46.75%. Given Atea Pharmaceuticals' higher possible upside, analysts plainly believe Atea Pharmaceuticals is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Collegium Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more volatility and risk, AVIR or COLL? Atea Pharmaceuticals has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Which has preferable earnings & valuation, AVIR or COLL? Collegium Pharmaceutical has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtea PharmaceuticalsN/AN/A-$135.96M-$1.65-1.75Collegium Pharmaceutical$664.28M1.44$48.15M$1.2224.46 Does the media prefer AVIR or COLL? In the previous week, Collegium Pharmaceutical had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 12 mentions for Collegium Pharmaceutical and 9 mentions for Atea Pharmaceuticals. Collegium Pharmaceutical's average media sentiment score of 1.36 beat Atea Pharmaceuticals' score of 0.36 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Collegium Pharmaceutical 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCollegium Pharmaceutical beats Atea Pharmaceuticals on 14 of the 17 factors compared between the two stocks. Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVIR vs. The Competition Export to ExcelMetricAtea PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$247.75M$6.58B$5.41B$8.53BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-1.409.2126.7719.96Price / SalesN/A257.57395.44121.37Price / CashN/A65.8538.2534.62Price / Book0.446.576.874.60Net Income-$135.96M$144.25M$3.23B$248.27M7 Day Performance13.53%5.13%5.32%2.28%1 Month Performance1.22%9.67%13.56%16.43%1 Year Performance-19.81%-0.88%17.86%8.15% Atea Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVIRAtea Pharmaceuticals2.4607 of 5 stars$2.90-0.2%$6.00+107.3%-19.4%$247.75MN/A-1.4070COLLCollegium Pharmaceutical4.113 of 5 stars$29.83-1.3%$43.80+46.8%-12.3%$958.50M$664.28M12.86210News CoveragePositive NewsNTLAIntellia Therapeutics4.668 of 5 stars$9.06+6.6%$36.90+307.3%-62.6%$938.46M$45.57M-1.67600Analyst ForecastHigh Trading VolumeRCUSArcus Biosciences3.5937 of 5 stars$8.70+1.6%$25.67+195.0%-47.4%$921.20M$141M-2.76500Positive NewsAVDLAvadel Pharmaceuticals2.2395 of 5 stars$9.35+3.8%$19.43+107.8%-40.3%$903.48M$194.45M-11.8470Positive NewsSYRESpyre Therapeutics2.3601 of 5 stars$14.88-2.0%$53.40+258.9%-58.2%$896.91M$890,000.00-1.99100Positive NewsGap DownPHVSPharvaris1.2993 of 5 stars$16.69+0.8%$40.67+143.7%-16.5%$872.72MN/A-5.9630CVACCureVac3.7447 of 5 stars$3.87+4.0%$14.00+261.8%+25.9%$868.19M$535.18M7.04880News CoverageUpcoming EarningsCRMDCorMedix2.151 of 5 stars$12.75+3.8%$15.00+17.6%+153.9%$864.77M$82.55M-15.7430Positive NewsNAGENiagen BioscienceN/A$10.93-0.2%N/AN/A$860.96M$107.93M64.29120BCAXBicara Therapeutics1.649 of 5 stars$15.21+5.1%$32.00+110.4%N/A$829.49MN/A0.0032Positive NewsAnalyst RevisionGap Up Related Companies and Tools Related Companies Collegium Pharmaceutical Alternatives Intellia Therapeutics Alternatives Arcus Biosciences Alternatives Avadel Pharmaceuticals Alternatives Spyre Therapeutics Alternatives Pharvaris Alternatives CureVac Alternatives CorMedix Alternatives Niagen Bioscience Alternatives Bicara Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVIR) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVIR Stock Free AVIR Stock Alerts